InsiderTrades.com logo
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
From Crypto Swap Profits   |   Ad
It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.
>> Register for the Workshop Now
Axel Bolte net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Axel Bolte Biography and Net Worth

CEO of Inozyme Pharma
Axel Bolte is our president and chief executive officer and is a member of our board of directors since September 2015, when he co-founded our company. Since March 2017, Mr. Bolte also has served as a managing member of Healthcare Advisors GmbH, a private healthcare advisory company. Mr. Bolte served as a venture partner at HBM Partners AG, a provider of investment advisor services in the life sciences industry, from February 2017 to September 2019 and as an investment advisor to HBM Partners AG from March 2003 to January 2017. Mr. Bolte currently serves on the board of directors of IVERIC bio, Inc. (formerly known as Ophthotech Corporation), or IVERIC, and previously served on the board of directors of Allena Pharmaceuticals, Inc., Nabriva Therapeutics plc and PTC Therapeutics, Inc., all of which are publicly traded biotechnology or pharmaceutical companies. Mr. Bolte received a degree in biochemistry from the Swiss Federal Institute of Technology, Zurich, Switzerland and an M.B.A. from the University of St. Gallen, Switzerland.

What is Axel Bolte's net worth?

The estimated net worth of Axel Bolte is at least $773,139.25 as of April 19th, 2022. Mr. Bolte owns 258,575 shares of Inozyme Pharma stock worth more than $773,139 as of December 22nd. This net worth approximation does not reflect any other assets that Mr. Bolte may own. Additionally, Mr. Bolte receives a salary of $1,160,000.00 as CEO at Inozyme Pharma. Learn More about Axel Bolte's net worth.

How old is Axel Bolte?

Mr. Bolte is currently 52 years old. There are 3 older executives and no younger executives at Inozyme Pharma. Learn More on Axel Bolte's age.

What is Axel Bolte's salary?

As the CEO of Inozyme Pharma, Inc., Mr. Bolte earns $1,160,000.00 per year. Learn More on Axel Bolte's salary.

How do I contact Axel Bolte?

The corporate mailing address for Mr. Bolte and other Inozyme Pharma executives is , , . Inozyme Pharma can also be reached via phone at 857-330-4340 and via email at [email protected]. Learn More on Axel Bolte's contact information.

Has Axel Bolte been buying or selling shares of Inozyme Pharma?

Axel Bolte has not been actively trading shares of Inozyme Pharma during the past quarter. Most recently, on Tuesday, April 19th, Axel Bolte bought 67,750 shares of Inozyme Pharma stock. The stock was acquired at an average cost of $3.69 per share, with a total value of $249,997.50. Following the completion of the transaction, the chief executive officer now directly owns 258,575 shares of the company's stock, valued at $954,141.75. Learn More on Axel Bolte's trading history.

Are insiders buying or selling shares of Inozyme Pharma?

In the last year, insiders at the sold shares 1 times. They sold a total of 7,523 shares worth more than $52,209.62. The most recent insider tranaction occured on April, 2nd when CEO Douglas A Treco sold 7,523 shares worth more than $52,209.62. Insiders at Inozyme Pharma own 11.2% of the company. Learn More about insider trades at Inozyme Pharma.

Information on this page was last updated on 4/2/2024.

Axel Bolte Insider Trading History at Inozyme Pharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/19/2022Buy67,750$3.69$249,997.50258,575View SEC Filing Icon  
6/24/2021Sell66,788$0.00$0.00257,613View SEC Filing Icon  
See Full Table

Axel Bolte Buying and Selling Activity at Inozyme Pharma

This chart shows Axel Bolte's buying and selling at Inozyme Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Inozyme Pharma Company Overview

Inozyme Pharma logo
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $2.99
Low: $2.75
High: $3.03

50 Day Range

MA: $3.65
Low: $2.48
High: $5.54

2 Week Range

Now: $2.99
Low: $2.38
High: $7.80

Volume

932,240 shs

Average Volume

457,722 shs

Market Capitalization

$192.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
From Crypto Swap Profits   |   Ad
It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.
>> Register for the Workshop Now